Department of Family Medicine, National Taiwan University Hospital Bei-Hu Branch, Taipei, Taiwan.
Department of Community and Family Medicine, National Taiwan University Hospital Hsinchu Branch, Hsinchu, Taiwan.
Int J Infect Dis. 2018 Aug;73:102-108. doi: 10.1016/j.ijid.2018.05.024. Epub 2018 Jun 12.
Despite the fact that vaccination is an effective primary prevention strategy for the containment of influenza outbreaks, health policymakers have shown great concern over the enormous costs involved in universal immunization, particularly when resources are limited.
A two-arm cost-effectiveness analysis (CEA) was conducted that took into account the aspect of herd immunity. The analysis used a study cohort of 100000 residents with a demographic make-up identical to that of the underlying population in Taipei County, Taiwan, during the epidemic influenza season of 2001-2002. The parameters embedded in the dynamic process of infection were estimated through the application of the newly proposed susceptible-infection-complication-recovery (SICR) model to the empirical data, in order to compute the number of deaths and complications averted due to universal vaccination compared to no vaccination. Incremental cost-effectiveness ratios (ICERs) and the cost-effectiveness acceptability curve (CEAC) given maximum amount of willingness-to-pay (WTP) were calculated to delineate the results of the two-arm CEA.
The incremental costs involved in the vaccinated group as compared to the unvaccinated group were $1195 to reduce one additional complication and $805 to avert one additional death, allowing for herd immunity. The corresponding figures were higher for the results without considering herd immunity. Given the ceiling ratio of WTP equal to $10000 (approximately two-thirds of GDP), the probability of the vaccination being cost-effective for averting death was 100% and for averting complications was 96.7%.
Universal vaccination against seasonal influenza was found to be very cost-effective, particularly when herd immunity is considered. The probability of being cost-effective was almost certain given the maximum amount of WTP within two-thirds of the GDP.
尽管疫苗接种是遏制流感爆发的有效初级预防策略,但卫生政策制定者对普遍免疫所涉及的巨大成本表示极大关注,尤其是在资源有限的情况下。
进行了两臂成本效益分析(CEA),考虑了群体免疫的方面。该分析使用了一个 100000 名居民的研究队列,其人口结构与台湾台北县 2001-2002 年流感流行季节的基础人口相同。通过将新提出的易感-感染-并发症-康复(SICR)模型应用于经验数据,估计了感染动态过程中嵌入的参数,以计算与不接种疫苗相比,普遍接种疫苗可避免的死亡和并发症人数。计算了增量成本效益比(ICER)和成本效益可接受性曲线(CEAC),给出了最大意愿支付(WTP)金额,以描绘两臂 CEA 的结果。
与未接种组相比,接种组的增量成本为减少 1 例额外并发症需额外支付 1195 美元,避免 1 例额外死亡需额外支付 805 美元,允许群体免疫。不考虑群体免疫的结果更高。考虑到 WTP 的上限比率等于 10000 美元(大约是 GDP 的三分之二),接种疫苗在预防死亡方面具有成本效益的概率为 100%,在预防并发症方面为 96.7%。
普遍接种季节性流感疫苗非常具有成本效益,特别是在考虑群体免疫的情况下。考虑到 GDP 的三分之二内的最大 WTP,具有成本效益的概率几乎是确定的。